Genomic testing of biopsies from patients with deadly, treatment-resistant cancerous blood syndromes called histiocytoses allowed doctors to identify genes fueling the ailments and use targeted molecular drugs to successfully treat them. Researchers recommend the regular use of comprehensive genomic profiling at diagnosis to positively impact clinical care.